Skip to main content
“Transforming Care and Inspiring Hope for all children…”

Genomic Medicine for Ill Neonates and Infants (GEMINI Study)

September 20, 2019
Andrea Trembath, MD, MPH of the Division of Neonatal-Perinatal Medicine is leading UNC-Chapel Hill’s involvement in the GEMINI Study. This multi-center, prospective clinical trial is designed to evaluate the clinical and economic utility of performing rapid whole genomic sequencing (vs. targeted genomic sequencing panels) in neonates and infants with suspected...

NIAID Calls for Commitment to STI Research to Surmount Growing Health Crisis

September 20, 2019
In 2017, the CDC reported 2.3 million new cases of sexually transmitted infections (STIs) in the United States. A. Fauci, MD, Director of the NIAID, addressed this growing health crisis in a perspective piece in The Journal of Infectious Diseases, highlighting the need for innovative research for diagnostics, therapeutics, and...

Jaspers Comments on Vaping Injuries and Safety Concerns in The Conversation

September 17, 2019
In a new piece written for the website The Conversation, Ilona Jaspers, PhD, speaks to the recent rise in cases of vaping-associated lung injury–and why vaping should not be considered a safe alternative to cigarettes. Dr. Jaspers, an inhalation toxicologist, studies how pollutants, inhaled chemicals and other particles affect human...

Hernandez and Carpenter Awarded Grant by the National Science Foundation

September 13, 2019
Young adults often monitor their health with wearable devices, which could also be used to improve their ability to detect worsening asthma symptoms. UNC-Chapel Hill and NCSU researchers, including Michelle Hernandez, MD, and Delesha Carpenter, PhD, MSPH, have been awarded an NSF grant to study early asthma exacerbation detection through...

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and Safety

September 9, 2019
People allergic to peanuts may have a new way to protect themselves from severe allergic reactions to accidental peanut exposure. It’s called sublingual immunotherapy – or SLIT – and it involves putting a minuscule amount of liquefied peanut protein under the tongue, where it is absorbed immediately into the blood...